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The biodistribution profiles in mice of two pyrrole-imidazole poly-
amides were determined by PET. Pyrrole-imidazole polyamides are
a class of small molecules that can be programmed to bind a broad
repertoire of DNA sequences, disrupt transcription factor-DNA
interfaces, and modulate gene expression pathways in cell culture
experiments. The 18F-radiolabeled polyamides were prepared by
oxime ligation between 4-[18F]-fluorobenzaldehyde and a hydrox-
ylamine moiety at the polyamide C terminus. Small animal PET
imaging of radiolabeled polyamides administered to mice revealed
distinct differences in the biodistribution of a 5-ring -linked
polyamide versus an 8-ring hairpin, which exhibited better overall
bioavailability. In vivo imaging of pyrrole-imidazole polyamides by
PET is a minimum first step toward the translation of polyamide-
based gene regulation from cell culture to small animal studies.
biodistribution  fluorine-18  oxime  radiosynthesis
The development of chemical agents to regulate aberrant geneexpression constitutes a promising strategy for treating hu-
man disease. These compounds function in cells by inhibiting the
translation of mRNA gene products or by antagonizing tran-
scription through direct DNA binding (1, 2). Pyrrole-imidazole
polyamides are a class of cell permeable oligomers programmed
to bind DNA sequence specifically with affinities similar to
transcription factors (2–4). Encoded by pairs of aromatic amino
acids N-methylpyrrole (Py) and N-methylimidazole (Im) (2),
polyamides have been shown to target a wide range of discrete
DNA sequences (5), localize to the nucleus in cell culture (6, 7),
and access chromatin (8, 9). Polyamides can regulate endoge-
nous gene expression through the disruption of DNA binding
proteins in the promoters of selected genes. The binding of
hypoxia-inducible factor (HIF-1) to the hypoxia response ele-
ment (HRE) has been antagonized by polyamides, resulting in
the decreased expression of HIF-1-regulated genes, including
VEGF (10, 11). Androgen receptor (AR) binding to androgen
response elements has also been inhibited by polyamides, yield-
ing decreased expression levels of AR-regulated genes, such as
prostate-specific antigen (12). A polyamide designed to inhibit
activating protein-1 binding in the promoter of TGF-1 facili-
tated decreased levels of TGF-1 expression in vitro and in vivo
(rats) (13). Gene activation has been achieved following poly-
amide treatment of a transcriptionally repressed cell culture
model of Friedreich’s ataxia (a trinucleotide repeat disease)
(14). Given these promising biological activities in cell culture,
tissue biodistribution studies of polyamides administered to
animals is highly warranted. In vivo imaging of polyamides in
discrete tissues would be of importance for the further devel-
opment of polyamide-mediated gene regulation in animal mod-
els, a pivotal step toward clinical applications.
A new paradigm in early drug discovery has been the utiliza-
tion of PET (15, 16). PET is an analytical imaging technology
that measures real-time biodistribution of a positron-emitting
probe administered to a subject. Through appropriate selection
of the radiolabeled probe, a variety of biochemical processes
relevant to human disease can be studied by PET (17, 18).
Outside of the clinic, small animal PET is widely used in basic
biomedical research and development, providing quantitative
assays for the study of gene expression, metabolism and signal
transduction, and drug biodistribution (15, 17–19). Preclinical
drug screening by PET has been exploited for elucidating small
molecule permeability to the blood-brain barrier (20, 21), and in
human microdosing studies of experimental therapeutics during
early clinical development (15, 16). In addition, the low-mass
dose of radiolabeled PET probes (ie, high specific activity
compounds injected at nanomolar concentrations, yielding pico-
moles of probe/g tissue) allows for detailed biodistribution
analysis of target drugs without perturbing normal biological
processes (17, 18).
In this study, we evaluated the real-time biodistribution of
two polyamides of different classes, a 5-ring -linked 1
(ImPyImPyIm-C3-18F) and an 8-ring hairpin 3 [CtPyPyIm-
(R)H2N-PyImPyPy-C3-18F], in mice with PET imaging [,
-alanine; Ct, 3-chlorothiophene-2-carboxylic acid; (R)H2N,
(R)-2,4-diaminobutyric acid]. Oxime ligation of radiolabeled
4-[18F]-f luorobenzaldehyde (6) with hydroxylamine-function-
alized 8 and 9 facilitated the rapid radiosynthesis of 1 and 3.
The DNA binding affinity of analogous 19F-functionalized 2
and 4 was determined by quantitative DNase I footprinting,
and the stability of the oxime linkage was evaluated in vitro and
in vivo. PET/CT analysis of 1 and 3 in normal C57 mice
revealed considerable liver uptake for both polyamides, with
rapid gastrointestinal (GI) tract clearance for -linked 1.
Interestingly, hairpin 3 exhibited substantially longer bioavail-
ability, with minimal GI or renal clearance after 2 hours.
Results
Radiosynthesis. 4-[18F]-f luorobenzaldehyde (6) was used as a
radiochemical synthon (22–25) for the preparation of 18F-labeled
1 and 3 (Fig. 1). Compound 6 was prepared by nucleophilic
f luorination of trimethylammonium benzaldehyde derivative 5
at elevated temperature in the presence of the K18F/Kryptofix
[2.2.2] complex (Scheme 1) (25). Aniline accelerated oxime
ligation (26) facilitated the conjugation of 6 to hydroxylamine-
functionalized 8 and 9 in radiochemical yields of 12% (for 1) and
7% (for 3). Both syntheses were completed (material was HPLC
purified) at 100 min after end of bombardment (EOB).
DNase I Footprinting. Quantitative DNase I footprint titrations
were performed with 19F-functionalized 2 and 4 to assess if the
aminooxy-linked label 7 affects DNA binding. The binding
affinity of 2 was measured on the 5-32P-PCR fragment from
plasmid pJWP-17 (Fig. 2) (27). 2 bound the designed match site
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with Ka  3.5  2.1  109 M1, which is approximately
sevenfold lower in binding affinity compared to the analogous
polyamide possessing a N,N-dimethylaminopropyl tail (27).
Hairpin 4 was studied on the 5-32P- PCR fragment from plasmid
pGL2-VEGF-Luc (see Fig. 2) (10). Compound 4 bound the
HRE match site with Ka  3.2  0.3  109 M1. This binding
affinity istwofold and eightfold lower compared to polyamides
of the same core sequence functionalized with an amide-linked
3,3-diamino-N-methyldipropylamine tail terminated by either
FITC (10) or an amide linked isophthalic acid moiety (28),
respectively.
Evaluation of Oxime Stability. The pH stability of 4 was studied in
vitro to evaluate the tolerance of the aminooxy linkage to acidic
or basic cleavage. Solutions of 4 were incubated in pH 2.5, 4.0,
7.0, and 10 buffers at 37°C for 4 h, and then analyzed by ultra
performance liquid chromatography-mass spectrometry
(UPLC-MS). No significant degradation of 4 was observed at
any pH examined [Fig. 3; MS data shown in supporting infor-
mation (SI) Fig. S1]. To further probe the stability of this labeling
strategy, 4-[18F]-f luorobenzaldehyde (6) was administered to a
normal C57 mouse and the biodistribution profile of 6 was
measured by PET. As shown in Fig. S2, rapid kidney uptake of
6was observed oneminute after i.v. injection, with near exclusive
bladder occupancy measured 30 min after treatment. This
biodistribution profile differs dramatically from data obtained by
PET imaging of 1 and 3 under identical conditions (Fig. 4).
Biodistribution. Radiolabeled 1 and 3 were administered intrave-
nously to male C57 mice (dosages shown in Table S1) and tissue
biodistribution was measured by PET/CT (Figs. 4 and 5). Both
polyamides localized rapidly to the liver immediately upon
injection, with 1 and 3 exhibiting (on average) 46% and 36% liver
occupancy, respectively, 4 min after injection (see Fig. 5A).
The 5-ring -linked 1 was readily cleared from the liver by
excretion through the gallbladder and entry into the small
intestine, with 35 to 40% of the radioactive dose observed in the
GI tract within the first 20 min. The 8-ring hairpin 3 exhibited
constant levels of liver occupancy throughout the duration of the
scan, and was excreted more slowly than 1 (eg, only 5% of the
radioactive dose measured in the GI after 20 min). Elimination
Fig. 2. Quantitative DNase I footprint titration experiments with 2 and 4.
Experiments were conducted on 5-[32P]-end-labeled PCR products of plasmid
pJWP-17 (27) (for 2) (A), or plasmid pGL2-VEGF-Luc (10) (for 4) (B). The match
binding sites are depicted on each gel (bracketed with M) and the correspond-
ing binding isotherms are shown. Lanes 1 to 15 on each gel correspond to the
following (in order): intact DNA, products of the G chemical sequencing
reaction, products of the A chemical sequencing reaction, DNase I standard, 1
pM (polyamide treatment), 3 pM, 10 pM, 30 pM, 100 pM, 300 pM, 1 nM, 3 nM,
10 nM, 30 nM, 100 nM.
Fig. 1. Structures of 1 to 4 and their DNA binding sites. Closed circles
designate N-methylimidazole, open circles designate N-methylpyrrole, dia-
monds represent -alanine, and squares represent 3-chlorothiophene. The
gray star designates the oxime-linked fluorine-18 or fluorine-19 label.
Scheme 1. Synthesis of 1–4. (a) K18F, Kryptofix [2.2.2], DMSO, 100°C, 10 min, 91%
(decay-corrected). (b) 6, 8, TFA (aqueous), aniline, MeOH, 100°C (sealed tube), 20
min, 12% (decay-corrected). (c) 7, 8, NH4OAc (aqueous), DMF, 40°C, 40 min, 49%.
(d) 6, 9, NH4OAc (aqueous), aniline, MeOH, 100°C (sealed tube), 20 min, 7%
(decay-corrected). (e) 7, 9, NH4OAc (aqueous), DMF, 40°C, 50 min, 41%.
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through the GI is favored over bladder excretion for both
compounds. A constant level of 1was observed in the gallbladder
throughout the entire PET scan, whereas no significant levels of
3 were detected. Neither polyamide exhibited significant activity
in the brain, heart, or bone.
Dosimetry. Biodistribution data obtained for 1 and 3 in mice were
used to estimate the dosimetry values for a human model. The
dose-limiting organ for 1 was the small intestine, with the urinary
bladder wall, gallbladder, liver, and upper intestines possessing
considerable radioactive doses (Table S2). For 3 the dose-
limiting organ was the kidneys, with significant radioactive dose
noted in the gallbladder, small intestine, liver, urinary bladder
wall, and upper and lower intestines (Table S3).
Discussion
Recently, the use of PET in early drug development has gained
considerable attention (15, 16). In this study, we assessed the
tissue bioavailability and overall biodistribution of two 18F-
labeled polyamides of different classes (1 and 3) in mice using
small animal PET.
The polyamide cores selected for biodistribution analysis in
this study exhibit promising biological activities in cell culture.
Fig. 3. pH stability analysis of 4. 4 was incubated in pH 2.5 (A), pH 4.0 (B), pH
7.0 (C), and pH 10 (D) buffers at 37°C for 4 h. Samples were neutralized by
addition of aqueous NH4OAc containing 9-aminoacridine (standard), and
then analyzed by UPLC-MS. DMI (1,3-dimethyl-2-imidazolidinone) (15%, vol/
vol) was used as a cosolvent in the incubation and neutralization steps.
Chromatograms shown (A–D) are UV detection at 254 nm. See Fig. S1 for MS
data.
Fig. 4. PET/CT images of mice administered 18F-labeled 1 (images A–C) and 3 (images D–F). Time-points shown are 1 min (A and D), 30 min (B and E), and 2 h
(C and F) after injection.
Fig. 5. Biodistribution of 18F-labeled 1 (shown inblack) and 3 (shown ingray)
in mice by PET analysis. (A) Liver (open circles) versus GI (closed squares)
occupancy for 1 and 3 over 2 h. (B and C) Remaining in vivo occupancy of 1 (B)
and 3 (C) in mice, excluding the liver and GI values shown in A.











The 5-ring -linked polyamide (ie, the core of 1 with an
N,N-dimethylaminopropyl tail) up-regulates expression of the
repressed gene frataxin in a cell culture model of the disease
Friedreich’s ataxia (14). The 8-ring hairpin polyamide (ie, the
core of 3) downregulates hypoxia-induced VEGF expression in
cell culture as either the FITC or isophthalic acid conjugate (10,
11, 28). Because the molecular recognition properties of poly-
amides are largely dictated by the arrangement of N-
methylpyrrole and N-methylimidazole amino acids (2), we chose
to append the polyamide C terminus (tail) with the 18F-labeled
prosthetic group to minimize its effects on DNA binding.
Although a variety of positron-emitting radioisotopes have
been used for PET imaging, f luorine-18 is often considered the
isotope of choice (29). Fluorine-18 possesses many favorable
characteristics for PET imaging, including short positron range
of travel in tissue, a suitable half-life (110 min), and a strong C–F
bond with minimal perturbations to the native compound for
monitoring a variety of biochemical processes in vivo (29, 30).
For the radiosynthesis of polyamides described in this study, we
used an oxime ligation between 4-[18F]-f luorobenzaldehyde (6)
and hydroxylamine-functionalized 8 and 9 to afford aminooxy-
labeled 1 and 3, respectively (see Scheme 1). This radiolabeling
strategy has found widespread utility in the chemoselective
radiolabeling of unprotected peptides for PET analysis (22–24),
and offers significant advantages for the preparation of radio-
labeled polyamides. For example, radiolabeled benzaldehyde 6 is
readily synthesized by nucleophilic 18F-fluorination of the tri-
f late salt 5, and easily purified on a solid-phase extraction
cartridge (25, 31). This initial purification eliminates unreacted
18F-fluoride ion carryover to the polyamide conjugation step.
Additionally, the chemoselectivity of the oxime-forming reac-
tion obviates the need to protect the chiral amine of 9, thereby
eliminating a deprotection step after radiolabeling. The recently
described aniline-promoted transimination methodology for
oxime synthesis was used in the radiosynthesis of 1 and 3 (26).
1 and 3 were prepared in overall radiochemical yields (decay-
corrected) of 12% and 7%, respectively, at100 min after EOB.
The specific activity of 3 was measured to be 2,000 Ci/mmole
at EOB, which demonstrates this methodology yields 18F-labeled
polyamides with high specific activities.
Quantitative DNase I footprint titrations were conducted to
assess the DNA-binding penalty resulting from addition of the
oxime-linked tag 6. Fluorine-19 analogues 2 and 4 (see Fig. 1)
were synthesized from commercially available 7 and evaluated
on the 5-32P-PCR fragments from plasmid pJWP-17 (27) and
pGL2-VEGF-Luc (10), respectively (see Fig. 2). -linked 2
bound the designed match site with Ka  3.5  2.1  109 M1
and hairpin 4 bound the HRE match site with Ka  3.2  0.3 
109 M1. These binding affinities were only slightly lower (
8-fold) than polyamides possessing the same cores but different
functionalities on the tail (10, 27, 28). Therefore, the DNA
binding penalty resulting from addition of the 18F-radiolabel is
minimal.
Although oxime conjugation of 6 to hydroxylamine-
functionalized peptides has been reported previously for PET
studies (22–24), we evaluated the pH tolerance of the oxime
linkage in vitro and studied its stability in vivo. To probe pH
stability, hairpin 4 was incubated in acidic (pH 2.5 and pH 4.0),
neutral (pH 7.0) and basic (pH 10) solutions at 37°C for 4 h.
Remarkably, no significant degradation of 4 was detected at any
pH examined by UPLC-MS analysis (see Fig. 3). To assess in vivo
stability of the 18F-labeled polyamide, we also obtained PET/CT
images of a mouse administered with 4-[18F]-f luorobenzalde-
hyde (6). We rationalized that rapid hydrolysis of the oxime bond
of 1 or 3 in vivo would liberate benzaldehyde 6 and yield similar
biodistribution profiles for all compounds examined. PET im-
aging of a mouse injected with 6 revealed rapid kidney uptake
of the tracer, followed by near exclusive bladder occupancy
within 30 min (see Fig. S2). On the other hand, extremely low
kidney and bladder uptake was observed for both polyamides in
this study (see Fig. 5), and clearance through the GI tract was
favored for both 1 and 3. Therefore, oxime hydrolysis and the
formation of 4-[18F]-f luorobenzaldehyde (6) following injection
seems quite unlikely.
The biodistribution profiles of a 5-ring -linked 1 and an 8-ring
hairpin 3 were evaluated by PET/CT imaging (see Figs. 4 and 5).
For both polyamides rapid liver uptake was observed, with (on
average) 46% (1) and 36% (3) of the injected radioactive dose
localized in the liver 4 min after injection. A steady decrease
in liver occupancy for -linked 1 was paralleled by rapid entry
into the gallbladder, followed by localization in the GI tract.
Approximately 35 to 40% of 1 was observed in the GI tract
within the first 20 min. This rapid clearance from the liver was
not observed with hairpin 3. After 20 min, only 5% of the
injected dose of 3 was measured in the GI tract. The diminished
pharmacokinetics of elimination for hairpin 3 suggests it pos-
sesses better overall bioavailability than -linked 1. Low levels of
radioactivity were detected in the kidneys and bladder for both
1 and 3, suggesting that excretion through the GI tract is the
predominant method of elimination. Gallbladder occupancy
remained constant throughout the duration of the scan for
-linked 1, whereas no radioactivity was detected for hairpin 3.
Insignificant radiotracer levels were detected in the brain for
both polyamides; therefore, neither 1 nor 3 crosses the blood-
brain barrier. Activity was not detected in the heart or bone for
either compound. Consequently, 18F-labeled 1 and 3 are not
defluorinated in vivo on the time scale of this experiment, as
evidence by the absence of [18F]-f luoride accumulation in bone.
The rapid elimination of 1 through the GI tract is reminiscent
of the poor bioavailability of antisense phosphodiester oligonu-
cleotides, another class of chemical agents used in gene regula-
tion applications. Multiple biodistribution studies with radiola-
beled (antisense) phosphodiester oligonucleotides have revealed
significant renal clearance within the first hour following injec-
tion in baboons (32) and rats (33, 34). Similar results were also
obtained in mice, with high radioactivity levels found in the
kidney at the same time point (35). A recent PET study in mice
treated with 64Cu radiolabeled siRNA revealed similar clearance
characteristics, with 23% of the injected dose measured in the
liver and 73% of the injected dose delivered to the bladder after
1 h (36). Packaging of the radiolabeled siRNA complex into a
nanoparticle did not significantly affect biodistribution. Com-
pared with these studies and 1, hairpin 3 is eliminated from the
mouse less rapidly.
The tissue biodistribution of two structurally-related, DNA-
binding small molecules, GSQ-2287 and Hoechst 33342, has
been reported. GSQ-2287, a synthetic analogue of the natural
product distamycin, localizes rapidly to the liver and kidney in
mice shortly after injection (at therapeutic dose) and fails to
cross the blood-brain barrier (37). Iodine-125 labeled Hoechst
33342 accumulates mostly in the kidneys (22% of injected dose),
liver and spleen (7% of injected dose each) 4 h after injection
(38). Aside from the kidney occupancies observed for both small
molecules, the high liver values and failure to cross the blood-
brain barrier is similar to data obtained for 1 and 3.
Two biodistribution studies of hairpin polyamides adminis-
tered to rodents have been reported previously. Dosage of a
10-ring (2--3 hairpin motif) f luorescein-labeled polyamide to
rats (5 mg dose/250 g body weight) revealed considerable renal
clearance at 24 h (13). This polyamide was also detected in the
aorta, liver, and lung at the same time point, whereas no
distribution to the heart or brain was observed. The liver uptake
of 1 and 3 presented herein is consistent with this data, although
1 and 3 were both eliminated through the GI tract preferentially
(see Fig. 5). It should be noted that GI tract occupancy was not
evaluated in the aforementioned study (13). Recently, the phar-
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macokinetics of a hairpin polyamide-chlorambucil conjugate
dosed to mice (500 nmoles per mouse) was evaluated at two
time-points (39). Predominant occupancy of the polyamide-
alkylator conjugate was observed in the lung, spleen, small
intestine, and pancreas at 2 and 24 h, as measured by liquid
chromatography-mass spectrometry analysis (39). Elimination
through the GI tract parallels the results obtained with 1 and 3
in this study. Interestingly, minimal liver occupancy was mea-
sured with the hairpin polyamide-alkylator conjugate at 2 h (39),
whereas 3 is predominantly localized in the liver at the same time
point.
Although both of the above-mentioned studies provide
insights into polyamide bioavailability (13, 39), the necessity of
animal killing and organ extraction permits only single time-
point measurements to be conducted per animal. The meth-
odology presented in this study permits examinations of
polyamide biodistribution at multiple time points in the same
animal, allowing detailed pharmacokinetic measurements to
be performed in only a few hours. An example of the utility of
this technology is shown in Fig. 5. As previously mentioned,
hairpin 3 exhibits greater liver occupancy than -linked 1 at
2 h. However, data obtained from PET imaging of 1 and 3 (see
Fig. 5 A) reveals 1 to possess greater overall liver occupancy
than hairpin 3 only minutes after injection. 1 is then rapidly
cleared from the liver and distributed into the GI tract,
whereas the level of hairpin 3 in the liver remains constant
throughout the scan. The differences in the pharmacokinetics
of elimination between 1 and 3 is readily observed by PET
imaging, whereas classical, single time-point methods for
studying compound biodistribution may fail to identify such
subtle disparities.
PET imaging of 18F-labeled 1 and 3 reveals distinct differences in
tissue bioavailability between the two classes of polyamides, and
constitutes the first bioavailability study of polyamides by this
technology. In addition, a robust oxime-based radiolabeling pro-
cedure for the general preparation of 18F-labeled polyamides has
been described. These advances constitute a new tool for the further
development of polyamide technology toward clinical applications,
allowing candidate polyamides to be screened for favorable bio-
availability properties during early chemical development.
Materials and Methods
Polyamide Synthesis. Protocols and Schemes S1–S4 for the synthesis of 18F-
labeled polyamides, fluorine-19 standards, and radiolabeling precursors can
be found in the SI Experimental Details. Analytical HPLC characterization of
18F-labeled compounds is shown in Fig. S3.
Determination of DNA Binding Affinities. Quantitative DNase I footprint titra-
tion experiments were conducted on 5-32P-PCR fragments from plasmid
pJWP-17 (27) (2) and pGL2-VEGF-Luc (10) (4). Detailed experimental protocols
have been reported previously (40).
pH Stability Analysis. Individual polyamide-buffer solutions were prepared by
dissolving polymaride 4 (15 l, 375 M solution in DMI) in pH 2.5, 4.0, 7.0, or
10 buffers (85 l, 20-mM high performance capillary electrophoresis grade
buffers from Fluka) or distilled and deionized water (see Fig. S1). The poly-
amide solutions were shaken at 37°C for 4 h. Samples were neutralized by
addition of a solution (100l) consisting of aqueous NH4OAc (100 mM, pH 6.5;
85%, vol/vol), DMI (15%, vol/vol), and 9-aminoacridine (5.0 M, Fluka) as
internal standard for UPLC-MS analysis. Samples were vortexed, sonicated
briefly (1 min), vortexed again, then immediately frozen in liquid nitrogen.
Samples were stored at 80°C until analyzed. UPLC-MS analysis was per-
formed on a Waters Acquity UPLC-LCT Premiere XE TOF-MS (ESI	) system (see
Fig. S1). A Waters Acquity UPLC BEH C18 column (2.1  50 mm, 1.7 m) was
used, with the mobile phase consisting of a gradient of MeCN (containing
0.1% formic acid) in formic acid (0.1%, aqueous). UV analysis was measured at
254 nm.
PET/CT Imaging. PET/CT imaging was conducted on male C57 mice under an
approved protocol by the University of California at Los Angeles Animal
Research Committee. Mice were kept warm, under 1 to 2% isoflurane gas
anesthesia, and positioned using an imaging chamber. Fluorine-18-labeled 1
and 3 and control 4-[18F]-fluorobenzaldehyde (6) were injected into the tail
vein (dosages shown in Table S1). Data were acquired using a Siemens Pre-
clinical Solutions microPET Focus 220 and microCAT II CT systems. PET data
were acquired for 2 or 3 h and reconstructed using filtered back projection
into 22 or 28 frames, respectively. PET images are1.8-mm resolution, 0.4-mm
voxel size. CT images are a low dose 400-m resolution acquisition with
200-m voxel size. Images were coregistered and regions drawn using AMIDE
software (Andreas Loening, amide.sourceforge.net, Version 0.8.16).
Calculation of Biodistribution Values. The biodistribution graphs contain the
percentage of total dose in each organ over 2 h. Liver values are based on a
region drawn away from the gallbladder, with the mean value multiplied by
the estimated weight derived from 4.5% of the mouse body weight (value
from The Jackson Laboratory Web site). Kidney, heart and brain totals are
from regions drawn on the PET images, and verified using the weights based
on literature values as percent body weight (assuming density equals 1, thus
volume equals weight). GI (1.75 g) and gallbladder (20 mg) weights are based
on literature search estimated organ weights for a 25-g mouse.
Calculation of Dosimetry Values. The total number of disintegrations was
calculated for each organ and the total body. The data were then extended to
7.5 h after injection to estimate the majority of the total number of disinte-
grations (4 half-lives for physical decay, accounting for 95% of all disin-
tegrations). No bladder voiding or bowel movements were assumed. Using
the residency time equivalent measure, dosimetry was calculated using
OLINDA software (Version 1.0, Vanderbilt University, 2003). The adult male
human model was used.
OLINDA is not designed for using PET data in mice to make human predic-
tions. There are no S table values for the small organ sizes and distances in
mice, so these data are preliminary and only provide a guide for estimating
limiting dosage for potential human use and should be followed with human
dosimetry to determine the proper dose limitations.
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